Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EFFECTA trial in giant cell arteritis
2023-506623-29-01Phase 2Authorised
- Sponsor
- Military Institute of Medicine – National Research Institute
- Start
- Mar 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in giant cell arteritis (GCA) comparing Etanercept arm with Methotrexate arm (2 arms). Primary endpoint: Sustained steroid-free giant cell arteritis remission at week 52. Planned start Mar 2025; status: authorised.
02
Drugs
etanerceptmethotrexate
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on 2023-506623-29-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506623-29-01.